Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities in a market manipulation lawsuit, alleging damages exceeding $700 million USD due to "spoofing" techniques that artificially depressed its stock price [1][2][4]. Legal Proceedings - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants engaged in market manipulation that violated the Securities Exchange Act of 1934 [2]. - Quantum BioPharma's amended complaint was filed on May 31, 2025, in response to the defendants' memorandum of law filed on June 16, 2025 [2][3]. Financial Implications - Quantum BioPharma is seeking over $700 million USD in damages due to the alleged market manipulation [2]. - The company's stock was trading over $460 USD per share in January 2020, with a market capitalization approaching $1 billion USD [5]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted an extensive investigation and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Background - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement that could yield up to $250 million [10].
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing